MARKET

SPRO

SPRO

Spero Therapeuti
NASDAQ
1.720
-0.030
-1.71%
After Hours: 1.700 -0.02 -1.16% 16:36 03/28 EDT
OPEN
1.750
PREV CLOSE
1.750
HIGH
1.760
LOW
1.720
VOLUME
153.71K
TURNOVER
0
52 WEEK HIGH
1.995
52 WEEK LOW
0.9900
MARKET CAP
92.65M
P/E (TTM)
3.996
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at SPRO last week (0318-0322)?
Weekly Report · 3d ago
Spero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy Rating
TipRanks · 03/18 10:26
Weekly Report: what happened at SPRO last week (0311-0315)?
Weekly Report · 03/18 09:18
Spero Therapeutics files $300M mixed securities shelf
Healthcare Spero Therapeutics files $300M mixed securities shelf Mar. 15, 2024 4:45 p.m. The company filed a prospectus related to a mixed shelf offering to raise up to $300m. The stock is down 1.7% in the last week.
Seeking Alpha · 03/15 20:45
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Limbach Holdings, Inc. Fell 14.7% to $42.42 on Thursday. The company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. Aptorum Group Limited and Presto Automation were among the stocks moving in today's mid-day session. Build-A-Bear Workshop and DICK'S Sporting Goods were also among the gainers.
Benzinga · 03/14 17:38
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Robinhood Markets, Inc. Shares rose sharply in today's pre-market trading after the company reported February trading metrics. The company's total funded customers grew to 23.6 million at the end of February. ShiftPixy, Inc., and Presto Automation Inc. Were among the stocks moving in pre- market trading.
Benzinga · 03/14 12:05
Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Spero Therapeutics Inc reports quarterly adjusted earnings of 96 cents per share for the quarter ended in December. Revenue rose 55% to $73.52 million from the same quarter last year. The company reported quarterly income of $51.19 million. The mean earnings estimate of three analysts was for a loss of 10 cents.
Reuters · 03/14 03:43
TD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)
TipRanks · 03/14 03:25
More
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.

Webull offers Spero Therapeutics Inc stock information, including NASDAQ: SPRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRO stock methods without spending real money on the virtual paper trading platform.